CBD vs. CBG vs. CBN: What Is the Difference?

CBD vs. CBG vs. CBN comparison table

The three cannabinoids share a plant source, but their research volume, common formulas and claims are not interchangeable.

What is CBD?

CBD is the most researched of the three and the dominant cannabinoid in many hemp extracts. It does not produce the characteristic intoxication associated with delta-9 THC. “Non-intoxicating,” however, should not be confused with inert or risk-free: CBD can change alertness and interact with medicines.

The FDA has approved one purified CBD prescription medicine for specific seizure disorders. That approval is evidence for a standardized drug, defined doses and monitored populations;not proof that retail oils or gummies treat unrelated conditions. Consumer products differ in dose, purity, other cannabinoids and oversight.

The FDA identifies drowsiness, gastrointestinal effects, potential liver injury and drug interactions among CBD concerns. Risk at common retail servings is not fully quantified, but a person using medicines should bring the exact label and serving to an interaction review.

Market categories often position CBD for calm or recovery. Human research spans anxiety, sleep, pain and other areas, but results and preparations vary. Choose a CBD product because its formula, amount and evidence fit the decision;not because “CBD” guarantees a feeling.

What is CBG?

CBG stands for cannabigerol. Its acidic precursor, CBGA, participates in plant pathways that produce several better-known cannabinoids. Marketing often calls CBG the “mother cannabinoid,” a memorable biochemical shorthand that does not demonstrate superior effects.

Controlled human evidence is still small. A 2024 crossover trial in 34 healthy adults tested 20 mg hemp-derived CBG and reported selected reductions in anxiety and stress without evidence of intoxication or impairment. It was a small acute study with multiple outcomes, not confirmation that CBG is a focus supplement or anxiety treatment.

A 2026 ascending-dose laboratory study tested CBG isolate across commercially relevant amounts in 12 healthy adults, adding useful pharmacokinetic and safety information but remaining too small for broad consumer promises. A separate veterans trial addressed sleep and found no clear objective sleep improvement.

CBG is commonly placed in daytime or focus formulas. Treat that as product positioning. For expected sensations, onset and duration, use the dedicated CBG edibles effects guide. If an oil causes tiredness, see why CBG oil may make someone sleepy.

What is CBN?

CBN stands for cannabinol. It can form as THC oxidizes over time, but a purified CBN ingredient is not equivalent to old cannabis or delta-9 THC. CBN is widely called the “sleep cannabinoid”; recent controlled trials make the story more specific and less certain.

A 2023 seven-night trial found that 20 mg CBN reduced nighttime awakenings and overall sleep disturbance versus placebo, while the primary sleep-quality effect did not reach conventional statistical significance. Adding CBD did not improve the CBN result, and there was no difference in sleep onset, wake after sleep onset or daytime fatigue.

A 2024 decentralized trial tested 25, 50 and 100 mg proprietary CBN formulas. All CBN groups improved a self-reported sleep-disturbance measure versus placebo, with no clear dose-response advantage and industry involvement that belongs in interpretation. A 2026 single-night crossover trial in 20 adults with insomnia found no significant change in its primary objective wake-after-sleep-onset measure at 30 or 300 mg, while selected secondary outcomes improved at 300 mg.

These are meaningful signals, not a universal verdict. Different doses, formulas, populations and endpoints produce different answers. CBN should not be marketed as proven to sedate everyone or treat insomnia. The dedicated guide asks the narrower question: is CBN psychoactive?

How should you choose between CBD, CBG and CBN?

Start with the routine and constraints. If you want the cannabinoid with the broadest human evidence, CBD has the lead;but also the clearest documented interaction and drowsiness concerns. If you are considering a daytime CBG formula, accept that direct human evidence remains small. If you are evaluating CBN for evening use, look at the exact dose and sleep outcome rather than assuming the category nickname is settled science.

Do not combine products to recreate an online “stack” without recalculating every cannabinoid. Two half servings can still duplicate CBD or THC. Alcohol, sedatives, antihistamines and other substances may increase impairment. If you feel drowsy, dizzy, slowed or altered, do not drive.

Isolate, broad-spectrum or full-spectrum?

“Entourage effect” language is a hypothesis, not automatic proof that more compounds work better. A blend can be convenient, but it also makes it harder to know which ingredient caused a benefit or side effect. Compare total cannabinoids per serving and individual amounts.

An oil offers adjustable volume but requires accurate measurement. Gummies are preportioned but can be difficult to split precisely. Vapes act differently and bring inhalation-specific risks. The same cannabinoid name does not make delivery formats equivalent.

How to read a CBD, CBG or CBN lab report

1. Match the lot. The report identifier should correspond to the product in hand.
2. Confirm the matrix. Finished oil or gummy results are more useful than raw extract results.
3. Compare units. Milligrams per gram, milliliter, unit and serving are not interchangeable.
4. Read every cannabinoid. Check CBD, CBG, CBN, delta-9 THC and any other quantified analytes.
5. Review contaminants. Confirm the report covers the relevant pesticide, solvent, heavy-metal and microbial panels.
6. Check recency and laboratory. A generic or undated certificate is weak evidence for a current batch.

For Mood products, start at the current lab-results library. If a result is hard to match to a bottle or serving, ask for clarification before use.

Sources and editorial review